There hasn't been a specific discussion around the issue of amphetamines with regard to the pharmaceutical industry paying for treatment or other services related to that. As you know, there have been a number of discussions happening in the area of opioids and ensuring that we are restricting the marketing ability of pharmaceutical companies associated with that.
